| Patient | Julius Caesar |
|---|---|
| Date of birth | 1972-07-12 |
| Identifiers | MRN HR-AC001-SYN; SSN (made up) 000-01-6022 |
| Document date | 2026-10-06 |
| Author | Lucius Fairbanks-Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Adult preventive visit; no new complaints. [S]
Julius Caesar returns for his adult preventive visit three weeks after his four-week review. The cold has gone. He has had no seizure or spell since starting levetiracetam seven weeks ago and has missed no doses. He takes lisinopril 10 mg, amlodipine 5 mg (added three weeks ago), atorvastatin 80 mg, and aspirin 81 mg without side effects; his home blood pressure readings have been 122 to 132 over 76 to 82. He is sleeping about seven hours a night, has a driver for all journeys, and rides only with a companion. He completed the health risk assessment before the visit. [S]
| Element | Detail |
|---|---|
| Visit | Adult preventive visit, age 54 |
| Active conditions | Focal epilepsy with a vascular cause; chronic left temporal infarct; hypertension; hyperlipidemia |
| Medicines | Levetiracetam 500 mg twice daily, lisinopril 10 mg, amlodipine 5 mg, atorvastatin 80 mg, aspirin 81 mg |
| Since the last visit | Cold resolved; no seizure; home blood pressure 122 to 132 over 76 to 82 |
| Functional status | Independent; working full days with less evening work |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good |
| Psychosocial | Demanding public work, supported by his staff; married; no money worries |
| Behavioral | Never smoker; a glass of wine once or twice a week (AUDIT-C 1); no other drug use; walks daily and rides at weekends with a companion |
| Nutrition | Mediterranean-style diet since the last visits; less salt |
| Activities of daily living | Independent in all |
| Instrumental activities of daily living | Manages his own medicines with a weekly pill box |
| Home safety | Smoke detectors working; showers rather than baths; no firearms |
| Sleep | About seven hours a night; vivid dreams less frequent |
| Driving | Not driving; a driver for all journeys |
| Hearing and vision | No hearing concern; reading glasses; no eye examination for three years |
| Falls | No falls apart from the collapse before his first visit |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight stable; no fever or night sweats |
| Eyes | Negative | No double or blurred vision |
| Ears, nose, mouth, and throat | Negative | Cold resolved; tongue healed |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No indigestion, bleeding, or change in bowel habit |
| Genitourinary | Negative | No urinary symptoms |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
| Integumentary | Negative | No rash or easy bruising |
| Neurological | Negative | No spell, weakness, numbness, or speech change; occasional mild tension headaches |
| Psychiatric | Negative | Mood steady; PHQ-2 score 0; no irritability now |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Lisinopril 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth each morning | Oral route | 2026-08-04 | active | S |
| Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily | 500 mg twice daily, morning and evening | Oral route | 2026-08-18 | active | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime | Oral route | 2026-08-18 | active | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth daily | One tablet by mouth daily with food | Oral route | 2026-08-18 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours as needed for fever or sore throat (no more than 3 g a day) | One or two tablets every 6 hours as needed, at most 3 g a day, for up to a week | Oral route | 2026-09-08 to 2026-09-14 | completed | S |
| Amlodipine 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth each morning | Oral route | 2026-09-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-06 | Body height | 182 | cm | S |
| 2026-10-06 | Body weight | 75.2 | kg | S |
| 2026-10-06 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 2026-10-06 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-10-06 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-10-06 | Heart rate | 66 | /min | S |
| 2026-10-06 | Respiratory rate | 14 | /min | S |
| 2026-10-06 | Body temperature | 36.6 | Cel | S |
| 2026-10-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-06 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-06 | Total score [AUDIT-C] | 1 | {score} | S |
Vital signs recorded on 2026-10-06; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; BMI 22.7 |
| Eyes | Pupils equal and reactive; fundi show mild arteriolar narrowing |
| Ears, nose, and throat | Normal |
| Neck | No bruit; no thyroid enlargement or nodes |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Respiratory | Clear |
| Abdomen | Soft, non-tender; no aortic pulsation felt |
| Musculoskeletal | Normal range of motion |
| Neurological | No focal deficit; normal gait |
| Skin | No suspicious lesions |
| Psychiatric | Calm and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent transient episodes of collapse: six days ago a witnessed collapse with stiffening and jerking of both arms for about a minute, a bitten tongue, and about twenty minutes of confusion, after a rising strange feeling and dizziness; two briefer spells of staring and unresponsiveness in the past eighteen months; cause not yet known (seizure, convulsive syncope, or transient ischemic attack) | resolved | confirmed | R56.9 | S — Synthetic presenting problem anchored to the documented accounts of falling attacks and fainting fits; it resolves when the cause is found. |
| Hypertension, stage 2: 152/94 and 148/92 mmHg today; told of high blood pressure about three years ago and never treated | active | confirmed | I10 | S — Synthetic vascular risk factor; no blood pressure from his lifetime is known. |
| Hyperlipidemia: LDL 158 mg/dL, triglycerides 170 mg/dL, HDL 44 mg/dL | active | confirmed | E78.5 | S — Synthetic vascular risk factor; no lipid value from his lifetime is known. |
| Focal epilepsy with a structural vascular cause: focal impaired-awareness seizures with automatisms, one evolving to a bilateral tonic-clonic seizure, arising from a chronic left temporal cortical infarct, with left temporal sharp waves on EEG | active | confirmed | G40.209 | S — Synthetic modern diagnosis anchored to the documented falling attacks; the ILAE 2017 seizure types and a structural cause are chosen for teaching and make no claim about what he had. |
| Chronic left posterior temporal cortical infarct, not recognized before the seizures, with moderate small-vessel white matter disease and a non-stenotic left carotid plaque; no residual deficit | active | confirmed | I69.398 | S — Synthetic modern finding anchored to the retrospective cerebrovascular hypothesis; it makes no claim about his real brain. |
| Acute viral upper respiratory infection with low-grade fever and poor sleep, three weeks after starting levetiracetam; rapid COVID-19 and influenza tests negative; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness, chosen to teach cold-remedy choices with hypertension, aspirin, and an antiseizure medicine, and sleep loss as a seizure trigger; it echoes no documented illness. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine, 2026-2027 | Completed today | Inactivated vaccine given today |
| Pneumococcal vaccine | Completed today | Recommended for all adults from age 50; PCV20 given today; no further pneumococcal dose needed |
| Recombinant zoster vaccine | Completed today | Dose 1 of 2 today; dose 2 in two to six months |
| COVID-19 vaccine, 2026-2027 | Due | Offered; he will have it at his pharmacy next week, away from today's three vaccines |
| Tetanus, diphtheria, and pertussis booster | Up to date | Tdap about seven years ago; next due in about three years |
| Hepatitis B vaccine | Up to date | He reports a completed series as a young army officer; record requested |
| Hepatitis C, hepatitis B, and HIV screening | Ordered | One-time screening for adults; no earlier result on record; drawn today with his consent |
| Blood pressure | Completed today | 128/80 mmHg on two medicines; target below 130/80 mmHg |
| Cholesterol | Up to date | On atorvastatin 80 mg since the infarct was found; lipid panel due at the ten-week review |
| Diabetes screening | Up to date | HbA1c 5.6 percent at intake; repeat in three years, or yearly if it reaches 5.7 |
| Colorectal cancer screening | Ordered | Never screened; recommended from 45. He chose colonoscopy, which is booked; aspirin can be continued for the procedure |
| Prostate cancer screening | Not indicated | Shared decision-making about PSA testing begins at 55; to be discussed at next year's visit |
| Depression screening | Completed today | PHQ-2 score 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C 1 |
| Tobacco use | Completed today | Never smoker |
| Lung cancer and abdominal aortic aneurysm screening | Not indicated | Never smoker; under the starting age for aneurysm screening |
| Eye examination | Due | None for three years; fundi show mild hypertensive narrowing; he will book an optometrist |
Immunizations given today: Influenza vaccine, 2026-2027 season; Recombinant zoster vaccine, dose 1 of 2; Pneumococcal conjugate vaccine (PCV20), single dose [S]
Guideline basis: Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Hepatitis C, hepatitis B, and HIV results by message. Colonoscopy as booked. Second zoster dose in two to six months. Ten-week chronic-care review in three weeks. Next preventive visit in one year. Next scheduled visit 2026-10-27: ten-week review: seizure control, lipids on atorvastatin, blood pressure, and driving and safety. [S]
Voluntary advance care planning discussion of about 20 minutes, with his consent, prompted by the finding of an old infarct on his scan. He named a health care agent and completed a health care power of attorney form; the agent is recorded in the chart and is not named here. He said he would want full treatment for any new stroke or prolonged seizure, including thrombolysis or thrombectomy if offered, and wants his agent and his neurologist told at once if he is admitted. He chose not to record other treatment preferences today. The plan will be revisited yearly or after any serious illness. [S]